Sarepta Therapeutics (SRPT) 55.12 $SRPT
Company News for September 20, 2016
Zacks Equity Research - Zacks Investment Research - 2 hrs 36 mins ago
Companies In The News are: BLOX,AVT,TECD,SRPT,ISLE,ERI
ISLE: 21.95 (-0.09), ERI: 13.40 (-0.44), AVT: 40.92 (-0.97), SRPT: 55.14 (+6.20), BLOX: 26.35 (unch), TECD: 87.93 (+3.13)
Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug
Zacks Equity Research - Zacks Investment Research - 2 hrs 48 mins ago
Sarepta (SRPT) announced that it gained an accelerated approval for its Duchenne muscular dystrophy (DMD) drug, Exondys 51 (eteplirsen), in the U.S.
BMRN: 98.42 (+0.31), ANIP: 65.75 (+2.00), SRPT: 55.14 (+6.20), ANIK: 47.65 (+0.16)
You Can’t Ignore the Biotech Breakout
Greg Guenthner - Daily Reckoning - Tue Sep 20, 8:46AM CDT
This post You Can’t Ignore the Biotech Breakout appeared first on Daily Reckoning . The major averages couldn’t hold onto their morning gains yesterday. Stocks spent the day slowly sinking into the red. But that didn’t stop a surprise FDA...
XBI: 67.55 (+1.66), SRPT: 55.14 (+6.20), PTCT: 10.03 (-0.96)
Advancing Preclinical Autoimmune Studies & Accelerated FDA Approvals Producing Rewards in Biotech Sector
PR Newswire - Tue Sep 20, 7:30AM CDT
Biotech & Pharma companies aim to create enhanced treatments & therapies for autoimmune diseases such as arthritis, cancer and other rare disease conditions through the latest preclinical studies, seeking accelerated FDA approvals and protocol assessments that include advancements from Sarepta Therapeutics, Inc. (NASDAQ: SRPT), Regen BioPharma Inc. (OTCBB: RGBP), Novavax, Inc. (NASDAQ: NVAX), PTC Therapeutics, Inc. (NASDAQ: PTCT) and Array BioPharma (NASDAQ: ARRY).
NVAX: 1.46 (-0.03), SRPT: 55.14 (+6.20), PTCT: 10.03 (-0.96), ARRY: 3.65 (-0.05)
Matrix Protein 1 (M1 or M) - Pipeline Review H2 2016 Featuring Novavax, Redbiotec AG & Sarepta Therapeutics - Research and Markets
BusinessWire - Tue Sep 20, 4:28AM CDT
Research and Markets has announced the addition of the "Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016" report to their offering.
SRPT: 55.14 (+6.20)
Isle of Capri, GM and Halliburton climb; WebMD drops
AP - Mon Sep 19, 4:15PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
JNJ: 117.95 (+0.29), ABT: 41.71 (+0.03), ISLE: 21.95 (-0.09), SRPT: 55.14 (+6.20), BLOX: 26.35 (unch), HAL: 41.32 (+0.04), GM: 31.43 (-0.29), TECD: 87.93 (+3.13), MS: 31.73 (+0.13)
Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51(TM) (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon 51
BusinessWire - Mon Sep 19, 12:39PM CDT
--U.S. Commercial Launch planned to commence immediately--
SRPT: 55.14 (+6.20)
CureDuchenne Celebrates FDA Approval of First Drug for Duchenne Muscular Dystrophy
BusinessWire - Mon Sep 19, 10:57AM CDT
CureDuchenne applauds the first-ever approval of a drug in the U.S. to treat Duchenne muscular dystrophy. The drug, Exondys 51 (eteplirsen), manufactured by Sarepta Therapeutics, Inc., received accelerated approval today from the Food and Drug Administration (FDA).
SRPT: 55.14 (+6.20)
Sarepta Shares Soar on News of Key Drug Critic FDA Exit
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 4:18PM CDT
Shares of Sarepta Therapeutics, Inc. (SRPT) rose around 27% on Wed, Sep 14 on news that a key critic, Farkas, of its lead pipeline candidate, eteplirsen, has left his job at the FDA - raising hopes of approval of the drug.
JNJ: 117.95 (+0.29), ANIP: 65.75 (+2.00), GERN: 2.06 (+0.06), SRPT: 55.14 (+6.20)
Mallinckrodt DMD Drug Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 8:57AM CDT
Mallinckrodt (MNK) received Fast Track status in the U.S. for its IND application for Synacthen Depot for the treatment of Duchenne muscular dystrophy.
MNK: 74.27 (-1.14), CATB: 4.05 (+0.09), ANIP: 65.75 (+2.00), SRPT: 55.14 (+6.20)
Research Report on Biotech Equities -- Celgene, Sarepta Therapeutics, MannKind, and Opko Health
PR Newswire - Wed Aug 24, 6:35AM CDT
Stock-Callers.com has on its radar four Biotech stocks, namely: Celgene Corp. (NASDAQ: CELG), Sarepta Therapeutics Inc. (NASDAQ: SRPT), MannKind Corp. (NASDAQ: MNKD), and Opko Health Inc. (NASDAQ: OPK). According to Transparency Market Research, the global white biotechnology market will grow at a CAGR of 4.5% over the period between 2016 and 2024. White biotechnology, or industrial biotechnology, comprises all the biotechnology uses related to industrial processes. Learn more about these stocks by accessing their free research reports at:
OPK: 10.41 (+0.10), SRPT: 55.14 (+6.20), MNKD: 0.71 (+0.01), CELG: 108.80 (+1.07), CELGZ: 1.21 (+0.01)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 308.16 (+4.66), BMRN: 98.42 (+0.31), SRPT: 55.14 (+6.20), ALXN: 131.36 (+0.18), IBB: 296.20 (+4.68), REGN: 406.31 (+3.48)
Sarepta Therapeutics Announces Common Stock Offering
BusinessWire - Thu Jun 09, 6:00AM CDT
Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that Sarepta, through Credit Suisse and Robert W. Baird & Co., agreed to sell an amount of its common stock equal to approximately $37.5 million in gross proceeds in an underwritten offering, before deducting underwriting discounts and commission and other estimated offering expenses.
SRPT: 55.14 (+6.20)
Sarepta Therapeutics Announces Proposed Offering
BusinessWire - Wed Jun 08, 3:19PM CDT
Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that Sarepta, through Credit Suisse and Robert W. Baird & Co., intends to sell an amount of its common stock equal to approximately $37.5 million in gross proceeds in an underwritten offering, before deducting underwriting discounts and commission and other estimated offering expenses.
SRPT: 55.14 (+6.20)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 308.16 (+4.66), SRPT: 55.14 (+6.20), ALXN: 131.36 (+0.18), AMGN: 173.90 (+2.52), ABBV: 63.39 (+0.48), REGN: 406.31 (+3.48), CELG: 108.80 (+1.07)
Sarepta Asked to Provide Dystrophin Data on Eteplirsen
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:23AM CDT
Sarepta (SRPT) announced that the FDA has requested for dystrophin data from biopsies on eteplirsen, as part of the ongoing evaluation of the NDA.
BMRN: 98.42 (+0.31), SRPT: 55.14 (+6.20), PFE: 33.80 (+0.15), BMY: 56.25 (+1.17)
Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA
BusinessWire - Mon Jun 06, 4:40PM CDT
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing evaluation of the eteplirsen New Drug Application (NDA). The Company plans to submit data from thirteen patient biopsy samples, at baseline and Week 48, to the FDA over the coming weeks to facilitate a prompt decision on the NDA by the Agency.
SRPT: 55.14 (+6.20)
Why Is Sarepta Therapeutics (SPRT) Stock Down 20% Today?
Ryan McQueeney - Zacks Investment Research - Thu Jun 02, 12:11PM CDT
Shares of Sarepta Therapeutics (SRPT) fell nearly 20% in early morning trading Thursday after new reports suggested that the Food and Drug Administration may force the company to offer its Duchenne muscular dystrophy (DMD) drug to patients at cost.
SRPT: 55.14 (+6.20)
Company News for September 20, 2016
Zacks Equity Research - Zacks Investment Research - 2 hrs 36 mins ago
Companies In The News are: BLOX,AVT,TECD,SRPT,ISLE,ERI
ISLE: 21.95 (-0.09), ERI: 13.40 (-0.44), AVT: 40.92 (-0.97), SRPT: 55.14 (+6.20), BLOX: 26.35 (unch), TECD: 87.93 (+3.13)
Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug
Zacks Equity Research - Zacks Investment Research - 2 hrs 48 mins ago
Sarepta (SRPT) announced that it gained an accelerated approval for its Duchenne muscular dystrophy (DMD) drug, Exondys 51 (eteplirsen), in the U.S.
BMRN: 98.42 (+0.31), ANIP: 65.75 (+2.00), SRPT: 55.14 (+6.20), ANIK: 47.65 (+0.16)
You Can’t Ignore the Biotech Breakout
Greg Guenthner - Daily Reckoning - Tue Sep 20, 8:46AM CDT
This post You Can’t Ignore the Biotech Breakout appeared first on Daily Reckoning . The major averages couldn’t hold onto their morning gains yesterday. Stocks spent the day slowly sinking into the red. But that didn’t stop a surprise FDA...
XBI: 67.55 (+1.66), SRPT: 55.14 (+6.20), PTCT: 10.03 (-0.96)
Advancing Preclinical Autoimmune Studies & Accelerated FDA Approvals Producing Rewards in Biotech Sector
PR Newswire - Tue Sep 20, 7:30AM CDT
Biotech & Pharma companies aim to create enhanced treatments & therapies for autoimmune diseases such as arthritis, cancer and other rare disease conditions through the latest preclinical studies, seeking accelerated FDA approvals and protocol assessments that include advancements from Sarepta Therapeutics, Inc. (NASDAQ: SRPT), Regen BioPharma Inc. (OTCBB: RGBP), Novavax, Inc. (NASDAQ: NVAX), PTC Therapeutics, Inc. (NASDAQ: PTCT) and Array BioPharma (NASDAQ: ARRY).
NVAX: 1.46 (-0.03), SRPT: 55.14 (+6.20), PTCT: 10.03 (-0.96), ARRY: 3.65 (-0.05)
Matrix Protein 1 (M1 or M) - Pipeline Review H2 2016 Featuring Novavax, Redbiotec AG & Sarepta Therapeutics - Research and Markets
BusinessWire - Tue Sep 20, 4:28AM CDT
Research and Markets has announced the addition of the "Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016" report to their offering.
SRPT: 55.14 (+6.20)
Isle of Capri, GM and Halliburton climb; WebMD drops
AP - Mon Sep 19, 4:15PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
JNJ: 117.95 (+0.29), ABT: 41.71 (+0.03), ISLE: 21.95 (-0.09), SRPT: 55.14 (+6.20), BLOX: 26.35 (unch), HAL: 41.32 (+0.04), GM: 31.43 (-0.29), TECD: 87.93 (+3.13), MS: 31.73 (+0.13)
Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51(TM) (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon 51
BusinessWire - Mon Sep 19, 12:39PM CDT
--U.S. Commercial Launch planned to commence immediately--
SRPT: 55.14 (+6.20)
CureDuchenne Celebrates FDA Approval of First Drug for Duchenne Muscular Dystrophy
BusinessWire - Mon Sep 19, 10:57AM CDT
CureDuchenne applauds the first-ever approval of a drug in the U.S. to treat Duchenne muscular dystrophy. The drug, Exondys 51 (eteplirsen), manufactured by Sarepta Therapeutics, Inc., received accelerated approval today from the Food and Drug Administration (FDA).
SRPT: 55.14 (+6.20)
Sarepta Shares Soar on News of Key Drug Critic FDA Exit
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 4:18PM CDT
Shares of Sarepta Therapeutics, Inc. (SRPT) rose around 27% on Wed, Sep 14 on news that a key critic, Farkas, of its lead pipeline candidate, eteplirsen, has left his job at the FDA - raising hopes of approval of the drug.
JNJ: 117.95 (+0.29), ANIP: 65.75 (+2.00), GERN: 2.06 (+0.06), SRPT: 55.14 (+6.20)
Mallinckrodt DMD Drug Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 8:57AM CDT
Mallinckrodt (MNK) received Fast Track status in the U.S. for its IND application for Synacthen Depot for the treatment of Duchenne muscular dystrophy.
MNK: 74.27 (-1.14), CATB: 4.05 (+0.09), ANIP: 65.75 (+2.00), SRPT: 55.14 (+6.20)
Research Report on Biotech Equities -- Celgene, Sarepta Therapeutics, MannKind, and Opko Health
PR Newswire - Wed Aug 24, 6:35AM CDT
Stock-Callers.com has on its radar four Biotech stocks, namely: Celgene Corp. (NASDAQ: CELG), Sarepta Therapeutics Inc. (NASDAQ: SRPT), MannKind Corp. (NASDAQ: MNKD), and Opko Health Inc. (NASDAQ: OPK). According to Transparency Market Research, the global white biotechnology market will grow at a CAGR of 4.5% over the period between 2016 and 2024. White biotechnology, or industrial biotechnology, comprises all the biotechnology uses related to industrial processes. Learn more about these stocks by accessing their free research reports at:
OPK: 10.41 (+0.10), SRPT: 55.14 (+6.20), MNKD: 0.71 (+0.01), CELG: 108.80 (+1.07), CELGZ: 1.21 (+0.01)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 308.16 (+4.66), BMRN: 98.42 (+0.31), SRPT: 55.14 (+6.20), ALXN: 131.36 (+0.18), IBB: 296.20 (+4.68), REGN: 406.31 (+3.48)
Sarepta Therapeutics Announces Common Stock Offering
BusinessWire - Thu Jun 09, 6:00AM CDT
Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that Sarepta, through Credit Suisse and Robert W. Baird & Co., agreed to sell an amount of its common stock equal to approximately $37.5 million in gross proceeds in an underwritten offering, before deducting underwriting discounts and commission and other estimated offering expenses.
SRPT: 55.14 (+6.20)
Sarepta Therapeutics Announces Proposed Offering
BusinessWire - Wed Jun 08, 3:19PM CDT
Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that Sarepta, through Credit Suisse and Robert W. Baird & Co., intends to sell an amount of its common stock equal to approximately $37.5 million in gross proceeds in an underwritten offering, before deducting underwriting discounts and commission and other estimated offering expenses.
SRPT: 55.14 (+6.20)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 308.16 (+4.66), SRPT: 55.14 (+6.20), ALXN: 131.36 (+0.18), AMGN: 173.90 (+2.52), ABBV: 63.39 (+0.48), REGN: 406.31 (+3.48), CELG: 108.80 (+1.07)
Sarepta Asked to Provide Dystrophin Data on Eteplirsen
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:23AM CDT
Sarepta (SRPT) announced that the FDA has requested for dystrophin data from biopsies on eteplirsen, as part of the ongoing evaluation of the NDA.
BMRN: 98.42 (+0.31), SRPT: 55.14 (+6.20), PFE: 33.80 (+0.15), BMY: 56.25 (+1.17)
Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA
BusinessWire - Mon Jun 06, 4:40PM CDT
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing evaluation of the eteplirsen New Drug Application (NDA). The Company plans to submit data from thirteen patient biopsy samples, at baseline and Week 48, to the FDA over the coming weeks to facilitate a prompt decision on the NDA by the Agency.
SRPT: 55.14 (+6.20)
Why Is Sarepta Therapeutics (SPRT) Stock Down 20% Today?
Ryan McQueeney - Zacks Investment Research - Thu Jun 02, 12:11PM CDT
Shares of Sarepta Therapeutics (SRPT) fell nearly 20% in early morning trading Thursday after new reports suggested that the Food and Drug Administration may force the company to offer its Duchenne muscular dystrophy (DMD) drug to patients at cost.
SRPT: 55.14 (+6.20)
